PDF
Full
Outline
Small cell lung cancer (SCLC) is characterized by a high degree of malignancy, with poor prognosis and high-growth fraction. About two-thirds of patients have developed distant metastasis at the time of diagnosis with rapid disease progression and high recurrence rates. Currently, topotecan-based chemotherapy remains the standard second-line treatment of SCLC with unfavorable disease remission, and less than one-fourth of patients have benefited from its efficacy. Chemotherapy-induced myelosuppression (CIM) is the most common toxicity in cancer chemotherapy, and severe CIM will reduce the dose intensity and anti-tumor efficacy of chemotherapy. Trilaciclib is a short-acting intravenous cyclin-dependent kinase 4/6 (CDK4/6) inhibitor administered prior to chemotherapy to preserve hematopoietic stem and progenitor cells and immune system function during chemotherapy, which has been approved by NMPA for prevention of CIM in SCLC in July 2022. Previous results showed that trilaciclib yielded favorable bone marrow protection during chemotherapy, but its anti-tumor effects in second-line treatment of SCLC have not been determined. This paper reports a case of a patient with advanced small-cell lung cancer with multiple metastases who obtained progression-free survival time of more than 1 year using trilaciclib combined with topotecan as second-line treatment.
PDF
43
18
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |
关闭全屏
No. 86 Xueyuan South Road, Haidian District, Beijing
010-62199257
qkjq@cast.org.cn
Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House
